Regaining health through Salmon discards

Projektinformationen

Salmino

ID Finanzhilfevereinbarung: 877747

DOI

10.3030/877747

Projekt abgeschlossen

EK-Unterschriftsdatum 18 Juli 2019

Startdatum 1 August 2019

Enddatum 30 November 2019

Finanziert unter

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Gesamtkosten

€ 71 429,00

EU-Beitrag

€ 50 000,00

Koordiniert durch

ZYMTECH LIFE SCIENCE AS
Norway

Periodic Reporting for period 1 - Salmino (Regaining health through Salmon discards)

Berichtszeitraum: 2019-08-01 bis 2019-11-30

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

Most nutritional supplement products currently available in the market, are plant or milk-based, extracted and produced by means of artificial processes. The majority do not have optimal absorption properties, leading to low bioavailability and efficacy.
Zymtech has developed AMIZATE®, a unique product produced by means of a natural enzymatic process from salmon proteins. AMIZATE® is rapidly absorbed after ingestion and contains all amino acids, small bioactive peptides (no larger than 561 Dalton), vitamins and minerals.
AMIZATE® can be used to manufacture an extensive portfolio of natural nutritional supplements for a wide variety of end users and with different purposes: sports recovery, general wellness, healthy ageing and medical nutrition.
The primary objective of the SALMINO project is to bring AMIZATE® to a large production and commercialization scale and perform clinical trials to support our health claims.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

Zymtech has developed and patented AMIZATE® with a production capability of up to 18,000 kg/month. Zymtech is already commercializing an AMIZATE®-based product in Europe and the US under the brand name “Unbroken” for cross fitters and athletes’ recovery after training. AMIZATE® is also available to be commercialized as an ingredient for nutraceutical products through a network of manufacturers and distributors.
During the period covered by the Feasibility Study, we have established pre-commercial agreements with partners for the commercialization of AMIZATE® in the EU, US and Asia and performed a thorough analysis of the protein hydrolysates market. We also have engaged with highly recognised key opinion leaders to support the dissemination of our product.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

We are committed to help the healthy people to stay healthy, the athletes to achieve their objectives and the patients to recover sooner. The main impact of our product upon market launch, will be the introduction of a unique product which is produced by means of a natural process and it is absorbed quicker into the blood stream, leading to an outstanding efficacy and a generalised improvement of several body functions. Our product is different because it is easily absorbed into the blood stream so it can carry out its function in the user’s body and it does not have any synthetic components.
AMIZATE® also has the potential to save health care costs by reducing the number of medical visits, hospital admissions as well as the length of hospital stays in the elderly and clinical segments.

image-1.png